Business
Publication of Peer-Reviewed Articles on VAL401
Publication of Peer-Reviewed Articles on VAL401.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 9778X ValiRx PLC 28 February 2017 \n\n \n \n \n \nValiRx Plc\n('ValiRx' or the 'Company')\n \nPEER-REVIEWED PUBLISHED ARTICLES SUPPORTING VALIRX & VALISEEK'S ANTI-CANCER TECHNOLOGY\n \nLondon, UK, 28 February 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces the recent publication of two articles in peer-reviewed journals that examine drug reprofiling in oncology and the progress of novel cancer treatment drug, VAL401, in its Clinical Efficacy trials for the treatment of lung cancer and other oncology indications.\n \nPublications\nThe first article is titled \"A Chemical Genomics Approach to Drug Reprofiling in Oncology: Antipsychotic Drug Risperidone as a Potential Adenocarcinoma Treatment\". Accepted for publication in Cancer Letters, Volume 393, 2017, Pages 16-21 and co-authored by Dr Suzy Dilly, Professor Paul Taylor, University of Leeds, alongside other academic staff at both the University of Warwick and Leeds University, this peer-reviewed communication details the experimental processes that led to the formulation of the VAL401 process. \n \nThe second publication is Bentham Science and is titled \"Pimping up Drugs Recovered, Superannuated and Under Exploited Drugs - An Introduction to the Basics of Drug Reprofiling\", Current Drug Discovery Technologies, 2017, 14, 000-000, by Dr George Morris, COO of ValiRx plc and Dr Suzy Dilly, CEO of ValiSeek. They explore examples of success in reprofiling, draw comparisons between techniques, and finally provide two examples from the ValiRx plc development pipeline currently undergoing the process.\nA third article appears as an advertising feature in the March 2017 issue of \"BioPharma Dealmakers\" (a Nature publication) describing the licensing opportunity of VAL401 as an oncology treatment and summarises the expectations of the current trial.\n \nFuture Conferences\nDr Victoria D'Aquino, Research and Development Officer at ValiRx, submitted an abstract on the current VAL201 clinical trial, which has been accepted for poster presentation at the 15th International Congress on Targeted Anti-Cancer Therapies (\"TAT\") in Paris, France, on 6-8 March 2017. \n \nDr Suzy Dilly will attend the Bio-Europe Spring bio-partnering conference on 20-22 March 2017, in Barcelona...